nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

10.06.2020

Chronic Granulomatous Disease: a Comprehensive Review

verfasst von: Hsin-Hui Yu, Yao-Hsu Yang, Bor-Luen Chiang

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency of phagocyte function due to defective NADPH oxidase (phox). Compared with the common types of CYBB/gp91^phox, NCF1/p47^phox, and CYBA/p22^phox deficiency, NCF4/p40^phox deficiency is a mild and atypical form of CGD without invasive bacterial or fungal infections. It can be diagnosed using serum-opsonized E.coli as a stimulus in dihydrorhodamine (DHR) assay. Patients with CYBC1/Eros deficiency, a new and rare form of CGD, present as loss of respiratory burst and gp91^phox expression in phagocytes. Neutrophils from patients with CGD are deficient in neutrophil extracellular traps (NETosis), autophagy, and apoptosis. The hyper-activation of NF-ĸB and inflammasome in CGD phagocytes also lead to long-lasting production of pro-inflammatory cytokines and inflammatory manifestations, such as granuloma formation and inflammatory bowel disease-like colitis. Patients with CGD and X-linked female carriers also have a higher incidence of autoimmune diseases. The implementation of antimicrobial, anti-fungal, and interferon-γ prophylaxis has greatly improved overall survival. Residual NADPH oxidase activity is significantly associated with disease severity and the chance of survival of the patient. New therapeutic approaches using immunomodulators for CGD-related inflammatory manifestations are under investigation, including pioglitazone, tamoxifen, and rapamycin. Hematopoietic stem cell transplantation (HSCT) is the curative treatment. Outcomes of HSCT have improved substantially over the last decade with overall survival more than 84–90%, but there are debates about designing optimal conditioning protocols using myeloablative or reduced-intensity regimens. The gene therapy for X-linked CGD using hematopoietic stem and progenitor cells transduced ex vivo by lentiviral vector encoding the human gp91phox gene demonstrated persistence of adequate oxidase-positive neutrophils in a small number of patients. Gene therapy using genome-editing technology such as CRISPR/Cas9 nucleases is a promising approach for patients with CGD in the future.

Nur mit Berechtigung zugänglich

Bridges RA, Berendes H, Good RA (1959) A fatal granulomatous disease of childhood: the clinical, pathological, and laboratory features of a new syndrome. JAMA Pediatr 97(4):387–408

Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL et al (2020) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol (ePub)

Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79(3):155–169CrossRef

Rider NL, Jameson MB, Creech CB (2018) Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J pediatric infect dis Soc 7 (suppl_1):S2-S5

Wolach B, Gavrieli R, de Boer M, van Leeuwen K, Berger-Achituv S, Stauber T, Ben Ari J, Rottem M, Schlesinger Y, Grisaru-Soen G, Abuzaitoun O, Marcus N, Zion Garty B, Broides A, Levy J, Stepansky P, Etzioni A, Somech R, Roos D (2017) Chronic granulomatous disease: clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patients. Am J Hematol 92(1):28–36PubMedCrossRef

Thomas DC, Charbonnier LM, Schejtman A, Aldhekri H, Coomber EL, Dufficy ER, Beenken AE, Lee JC, Clare S, Speak AO, Thrasher AJ, Santilli G, al-Mousa H, Alkuraya FS, Chatila TA, Smith KGC (2019) EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J Allergy Clin Immunol 143(2):782–785 e781PubMedCrossRef

Thomas DC, Clare S, Sowerby JM, Pardo M, Juss JK, Goulding DA, van der Weyden L, Storisteanu D, Prakash A, Espéli M, Flint S, Lee JC, Hoenderdos K, Kane L, Harcourt K, Mukhopadhyay S, Umrania Y, Antrobus R, Nathan JA, Adams DJ, Bateman A, Choudhary JS, Lyons PA, Condliffe AM, Chilvers ER, Dougan G, Smith KGC (2017) Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. J Exp Med 214(4):1111–1128PubMedPubMedCentralCrossRef

Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A (2010) Intracellular generation of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic Biol Med 49(12):1834–1845PubMedCrossRef

Dahlgren C, Karlsson A, Bylund J (2019) Intracellular neutrophil oxidants: from laboratory curiosity to clinical reality. J Immunol 202(11):3127–3134PubMedCrossRef

10.

Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, Reichenbach J (2009) Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114(13):2619–2622PubMedPubMedCentralCrossRef

11.

Sharma A, McCann K, Tripathi JK, Chauhan P, Zerbe C, Mishra BB, Holland SM et al (2019) Tamoxifen restores extracellular trap formation in neutrophils from patients with chronic granulomatous disease in a reactive oxygen species-independent manner. J allergy Clin Immunol 144 (2):597-600.e593

12.

Trevelin SC, Shah AM, Lombardi G (2020) Beyond bacterial killing: NADPH oxidase 2 is an immunomodulator. Immunol Lett 221:39–48PubMedCrossRef

13.

van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, Netea MG (2010) Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A 107(7):3030–3033PubMedPubMedCentralCrossRef

14.

Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A (2010) Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116(9):1570–1573PubMedPubMedCentralCrossRef

15.

Thomas DC (2018) How the phagocyte NADPH oxidase regulates innate immunity. Free Radic Biol Med 125:44–52PubMedCrossRef

16.

Deffert C, Carnesecchi S, Yuan H, Rougemont AL, Kelkka T, Holmdahl R, Krause KH, Schäppi MG (2012) Hyperinflammation of chronic granulomatous disease is abolished by NOX2 reconstitution in macrophages and dendritic cells. J Pathol 228(3):341–350PubMedCrossRef

17.

Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79(3):170–200CrossRef

18.

Kuhns DB, Hsu AP, Sun D, Lau K, Fink D, Griffith P, Huang DW, Priel DAL, Mendez L, Kreuzburg S, Zerbe CS, de Ravin SS, Malech HL, Holland SM, Wu X, Gallin JI (2019) NCF1 (p47(phox))-deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysis. Blood Adv 3(2):136–147PubMedPubMedCentralCrossRef

19.

Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, Scheible R, Rusch S, Gasteiger LM, Grimbacher B, Mahlaoui N, Ehl S, Abinun M, Albert M, Cohen SB, Bustamante J, Cant A, Casanova JL, Chapel H, de Saint Basile G, de Vries E, Dokal I, Donadieu J, Durandy A, Edgar D, Espanol T, Etzioni A, Fischer A, Gaspar B, Gatti R, Gennery A, Grigoriadou S, Holland S, Janka G, Kanariou M, Klein C, Lachmann H, Lilic D, Manson A, Martinez N, Meyts I, Moes N, Moshous D, Neven B, Ochs H, Picard C, Renner E, Rieux-Laucat F, Seger R, Soresina A, Stoppa-Lyonnet D, Thon V, Thrasher A, van de Veerdonk F, Villa A, Weemaes C, Warnatz K, Wolska B, Zhang SY (2019) The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract 7(6):1763–1770PubMedCrossRef

20.

Ochs HD, Igo RP (1973) The NBT slide test: a simple screening method for detecting chronic granulomatous disease and female carriers. J Pediatr 83(1):77–82PubMedCrossRef

21.

Yu JE, Azar AE, Chong HJ, Jongco AM, 3rd, Prince BT (2018) Considerations in the diagnosis of chronic granulomatous disease. J pediatric infect dis Soc 7 (suppl_1):S6-S11

22.

Roos D, de Boer M (2014) Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol 175(2):139–149PubMedPubMedCentralCrossRef

23.

Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DAL, Soule BP, Zarember KA, Malech HL, Holland SM, Gallin JI (2010) Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 363(27):2600–2610PubMedPubMedCentralCrossRef

24.

van de Geer A, Nieto-Patlan A, Kuhns DB, Tool AT, Arias AA, Bouaziz M, de Boer M et al (2018) Inherited p40phox deficiency differs from classic chronic granulomatous disease. J Clin Invest 128(9):3957–3975PubMedPubMedCentralCrossRef

25.

Peng J, Redman CM, Wu X, Song X, Walker RH, Westhoff CM, Lee S (2007) Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. Gene 392(1–2):142–150PubMedPubMedCentralCrossRef

26.

Bustamante J, Arias AA, Vogt G, Picard C, Galicia LB, Prando C, Grant AV, Marchal CC, Hubeau M, Chapgier A, de Beaucoudrey L, Puel A, Feinberg J, Valinetz E, Jannière L, Besse C, Boland A, Brisseau JM, Blanche S, Lortholary O, Fieschi C, Emile JF, Boisson-Dupuis S, al-Muhsen S, Woda B, Newburger PE, Condino-Neto A, Dinauer MC, Abel L, Casanova JL (2011) Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 12(3):213–221PubMedPubMedCentralCrossRef

27.

Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, Thurman G, Gonzalez-Aller C, Hiester A, deBoer M, Harbeck RJ, Oyer R, Johnson GL, Roos D (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci 97(9):4654–4659PubMedPubMedCentralCrossRef

28.

Milligan KL, Mann D, Rump A, Anderson VL, Hsu AP, Kuhns DB, Zerbe CS, Holland SM (2016) Complete myeloperoxidase deficiency: beware the "false-positive" Dihydrorhodamine oxidation. J Pediatr 176:204–206PubMedCrossRef

29.

van Bruggen R, Bautista JM, Petropoulou T, de Boer M, van Zwieten R, Gomez-Gallego F, Belohradsky BH et al (2002) Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 100(3):1026–1030PubMedCrossRef

30.

Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, Yockey L, Darnell DN, Barnhart L, Daub J, Boris L, Rump AP, Anderson VL, Haney C, Kuhns DB, Rosenzweig SD, Kelly C, Zelazny A, Mason T, DeRavin SS, Kang E, Gallin JI, Malech HL, Olivier KN, Uzel G, Freeman AF, Heller T, Zerbe CS, Holland SM (2015) Common severe infections in chronic granulomatous disease. Clin Infect Dis 60(8):1176–1183PubMedCrossRef

31.

Thomsen IP, Smith MA, Holland SM, Creech CB (2016) A comprehensive approach to the Management of Children and Adults with chronic granulomatous disease. J Allergy Clin Immunol Pract 4(6):1082–1088PubMedCrossRef

32.

Blancas-Galicia L, Santos-Chavez E, Deswarte C, Mignac Q, Medina-Vera I, Leon-Lara X, Roynard M et al (2020) Genetic, immunological, and clinical features of the first Mexican cohort of patients with chronic granulomatous disease. J Clin Immunol (ePub) 40:475–493CrossRef

33.

Falcone EL, Petts JR, Fasano MB, Ford B, Nauseef WM, Neves JF, Simoes MJ et al (2016) Methylotroph infections and chronic granulomatous disease. Emerg Infect Dis 22(3):404–409PubMedPubMedCentralCrossRef

34.

Reichenbach J, Lopatin U, Mahlaoui N, Beovic B, Siler U, Zbinden R, Seger RA, Galmiche L, Brousse N, Kayal S, Güngör T, Blanche S, Holland SM (2009) Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 49(11):1703–1710PubMedCrossRef

35.

Leiding JW, Holland SM (2012 [updated 2016]) chronic granulomatous disease. In: Adam MP, Ardinger HH, Pagon RA et al. (eds) GeneReviews® [internet]. Seattle (WA). University of Washington, Seattle; 1993-2020

36.

Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E, Jr., Deswarte C et al (2016) Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol 138 (1):241–248.e243

37.

Haidar G, Zerbe CS, Cheng M, Zelazny AM, Holland SM, Sheridan KR (2017) Phellinus species: an emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease. Mycoses 60(3):155–160PubMedCrossRef

38.

Sanmun D, Witasp E, Jitkaew S, Tyurina YY, Kagan VE, Ahlin A, Palmblad J et al (2009) Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol 297(3):C621–C631PubMedCrossRef

39.

Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 104(1):117–124PubMedCrossRef

40.

Connelly JA, Marsh R, Parikh S, Talano JA (2018) Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: controversies and state of the art. J pediatric infect dis Soc 7 (suppl_1):S31-S39

41.

Dunogue B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, Noel N et al (2017) Chronic granulomatous disease in patients reaching adulthood: a Nationwide study in France. Clin Infect Dis 64(6):767–775PubMedCrossRef

42.

Parekh C, Hofstra T, Church JA, Coates TD (2011) Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatr Blood Cancer 56(3):460–462PubMedCrossRef

43.

Alvarez-Cardona A, Rodriguez-Lozano AL, Blancas-Galicia L, Rivas-Larrauri FE, Yamazaki-Nakashimada MA (2012) Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. J Clin Immunol 32(2):207–211PubMedCrossRef

44.

Wei A, Ma H, Zhang L, Li Z, Zhang Q, Wang D, Zhang L, Lian H, Zhang R, Wang T (2020) Hemophagocytic lymphohistiocytosis resulting from a cytokine storm triggered by septicemia in a child with chronic granuloma disease: a case report and literature review. BMC Pediatr 20(1):100PubMedPubMedCentralCrossRef

45.

Bielorai B, Toren A, Wolach B, Mandel M, Golan H, Neumann Y, Kaplinisky C, Weintraub M, Keller N, Amariglio N, Paswell J, Rechavi G (2000) Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 26(9):1025–1028PubMedCrossRef

46.

Marciano BE, Allen ES, Conry-Cantilena C, Kristosturyan E, Klein HG, Fleisher TA, Holland SM, Malech HL, Rosenzweig SD (2017) Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: the NIH experience. J Allergy Clin Immunol 140(2):622–625PubMedPubMedCentralCrossRef

47.

Slack MA, Thomsen IP (2018) Prevention of infectious complications in patients with chronic granulomatous disease. J pediatric infect dis Soc 7 (suppl_1):S25-S30

48.

Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P (1983) NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med 99(5):657–674PubMedCrossRef

49.

Margolis DM, Melnick DA, Alling DW, Gallin JI (1990) Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 162(3):723–726PubMedCrossRef

50.

Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, Holland SM (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 348(24):2416–2422PubMedCrossRef

51.

Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debre M, Beaute J, Lortholary O et al (2011) Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 53(12):e159–e169PubMedCrossRef

52.

A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group (1991). N Engl J Med 324 (8):509–516

53.

Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, de Mattia D, IPINET. (2008) Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 126(2):155–164PubMedCrossRef

54.

Naderi beni F, Fattahi F, Mirshafiey A, Ansari M, Mohsenzadegan M, Movahedi M, Pourpak Z et al (2012) Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. Int Immunopharmacol 12 (4):689–693

55.

Oikonomou V, Moretti S, Renga G, Galosi C, Borghi M, Pariano M, Puccetti M, Palmerini CA, Amico L, Carotti A, Prezioso L, Spolzino A, Finocchi A, Rossi P, Velardi A, Aversa F, Napolioni V, Romani L (2016) Noncanonical fungal autophagy inhibits inflammation in response to IFN-gamma via DAPK1. Cell Host Microbe 20(6):744–757PubMedPubMedCentralCrossRef

56.

Chen LE, Minkes RK, Shackelford PG, Strasberg SM, Kuo EY, Langer JC (2003) Cut it out: managing hepatic abscesses in patients with chronic granulomatous disease. J Pediatr Surg 38(5):709–713PubMedCrossRef

57.

Straughan DM, McLoughlin KC, Mullinax JE, Marciano BE, Freeman AF, Anderson VL, Uzel G et al (2018) The changing paradigm of Management of Liver Abscesses in chronic granulomatous disease. Clin Infect Dis 66(9):1427–1434PubMedCrossRef

58.

Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM (2010) Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 51(12):1429–1434PubMedPubMedCentralCrossRef

59.

de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, Begun J, Plantinga TS, Joosten LAB, van der Meer JWM, Chamilos G, Netea MG, Xavier RJ, Dinarello CA, Romani L, van de Veerdonk FL (2014) IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A 111(9):3526–3531PubMedPubMedCentralCrossRef

60.

Hahn KJ, Ho N, Yockey L, Kreuzberg S, Daub J, Rump A, Marciano BE, Quezado M, Malech HL, Holland SM, Heller T, Zerbe CS (2015) Treatment with Anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis. Am J Gastroenterol 110(6):938–939PubMedCrossRef

61.

Gabrion A, Hmitou I, Moshous D, Neven B, Lefevre-Utile A, Diana JS, Suarez F et al (2017) Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease. J allergy Clin Immunol 139 (5):1641-1649.e1646

62.

Fernandez-Boyanapalli RF, Frasch SC, Thomas SM, Malcolm KC, Nicks M, Harbeck RJ, Jakubzick CV et al (2015) Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease. J allergy Clin Immunol 135 (2):517-527.e512

63.

Hule GP, Bargir UA, Kulkarni M, Kambli P, Taur P, Desai M, Madkaikar MR (2019) Does pioglitazone Lead to neutrophil extracellular traps formation in chronic granulomatous disease patients? Front Immunol 10:1739PubMedPubMedCentralCrossRef

64.

Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL (2010) PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 116(22):4512–4522PubMedPubMedCentralCrossRef

65.

Migliavacca M, Assanelli A, Ferrua F, Cicalese MP, Biffi A, Frittoli M, Silvani P et al (2016) Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J allergy Clin Immunol 137 (6):1913-1915.e1912

66.

Douda DN, Khan MA, Grasemann H, Palaniyar N (2015) SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. Proc Natl Acad Sci U S A 112(9):2817–2822PubMedPubMedCentralCrossRef

67.

Ahlin A, Fasth A (2015) Chronic granulomatous disease - conventional treatment vs. hematopoietic stem cell transplantation: an update. Curr Opin Hematol 22(1):41–45PubMedCrossRef

68.

Cole T, McKendrick F, Titman P, Cant AJ, Pearce MS, Cale CM, Goldblatt D, Gennery AR (2013) Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol 33(1):8–13PubMedCrossRef

69.

Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371(4):339–348PubMedPubMedCentralCrossRef

70.

de la Morena MT, Nelson RP Jr (2014) Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review. Clin Rev Allergy Immunol 46(2):131–144PubMedCrossRef

71.

Kekre N, Antin JH (2014) Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 124(3):334–343PubMedCrossRef

72.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A (2019) Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. The Lancet Haematology 6(11):e573–e584PubMedCrossRef

73.

Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, Dezern AE, Steppan D, Robey N, Holuba MJ, Cooke KR, Symons HJ (2016) Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders. Biol Blood Marrow Transplant 22(5):895–901PubMedPubMedCentralCrossRef

74.

Hoenig M, Niehues T, Siepermann K, Jacobsen EM, Schutz C, Furlan I, Duckers G et al (2014) Successful HLA haploidentical hematopoietic SCT in chronic granulomatous disease. Bone Marrow Transplant 49(10):1337–1338PubMedCrossRef

75.

Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano JA, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo ME, Veys P, Sykora KW, Gennery AR, Slatter M (2016) Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood 128(3):440–448PubMedPubMedCentralCrossRef

76.

Arnold DE, Seif AE, Jyonouchi S, Sullivan KE, Bunin NJ, Heimall JR (2019) Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. J Allergy Clin Immunol Pract 7(3):1052–1054 e1052PubMedCrossRef

77.

Yonkof JR, Gupta A, Fu P, Garabedian E, Dalal J (2019) Role of allogeneic hematopoietic stem cell transplant for chronic granulomatous disease (CGD): a report of the United States Immunodeficiency Network. J Clin Immunol 39(4):448–458PubMedCrossRef

78.

Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C et al (2014) Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 383(9915):436–448PubMedCrossRef

79.

Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J, Kreuzburg S et al (2018) X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability. J Allergy Clin Immunol 141(1):365–371PubMedCrossRef

80.

Battersby AC, Braggins H, Pearce MS, Cale CM, Burns SO, Hackett S, Hughes S et al (2017) Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. J allergy Clin Immunol 140 (2):628-630.e626

81.

Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL et al (2019) Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT. J Clin Immunol 39(7):653–667PubMedPubMedCentralCrossRef

82.

Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12(4):401–409PubMedCrossRef

83.

Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, Malech HL (2010) Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115(4):783–791PubMedPubMedCentralCrossRef

84.

Kohn DB, Booth C, Kang EM, Pai SY, Shaw KL, Santilli G, Armant M et al (2020) Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat med (ePub)

85.

Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49–55PubMedCrossRef

86.

Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11(9):636–646PubMedCrossRef

87.

Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346 (6213):1258096

88.

Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420–424PubMedPubMedCentralCrossRef

89.

Klatt D, Cheng E, Philipp F, Selich A, Dahlke J, Schmidt RE, Schott JW, Büning H, Hoffmann D, Thrasher AJ, Schambach A (2019) Targeted repair of p47-CGD in iPSCs by CRISPR/Cas9: functional correction without cleavage in the highly homologous Pseudogenes. Stem Cell Reports 13(4):590–598PubMedPubMedCentralCrossRef

90.

Battersby AC, Cale AM, Goldblatt D, Gennery AR (2013) Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. J Clin Immunol 33(8):1276–1284PubMedCrossRef

91.

Cale CM, Morton L, Goldblatt D (2007) Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 148(1):79–84PubMedPubMedCentralCrossRef

92.

Hauck F, Koletzko S, Walz C, von Bernuth H, Klenk A, Schmid I, Belohradsky BH et al (2016) Diagnostic and treatment options for severe IBD in female X-CGD carriers with non-random X-inactivation. J Crohns Colitis 10(1):112–115PubMedCrossRef

93.

Ahlin A, Fugelang J, de Boer M, Ringden O, Fasth A, Winiarski J (2013) Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr 102(11):1087–1094PubMed

94.

Khandelwal P, Bleesing JJ, Davies SM, Marsh RA (2016) A single-center experience comparing Alemtuzumab, Fludarabine, and Melphalan reduced-intensity conditioning with Myeloablative Busulfan, cyclophosphamide, and antithymocyte globulin for chronic granulomatous disease. Biol Blood Marrow Transplant 22(11):2011–2018PubMedCrossRef

95.

Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, Dowey SN, Cheng L, Malech HL (2011) Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117(21):5561–5572PubMedPubMedCentralCrossRef

96.

Flynn R, Grundmann A, Renz P, Hanseler W, James WS, Cowley SA, Moore MD (2015) CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Exp Hematol 43 (10):838-848.e833

97.

Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, Priel DL, Kuhns DB, Wang H, Vasilevsky S, de Ravin SS, Winkler T, Dunbar CE, Zou J, Zarember KA, Gallin JI, Holland SM, Malech HL (2015) An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol Ther 23(1):147–157PubMedCrossRef

98.

Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, Timm B, Siler U, Reichenbach J, Grez M, Moritz T, Schambach A, Cathomen T (2015) TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials 69:191–200PubMedCrossRef

99.

De Ravin SS, Reik A, Liu PQ, Li L, Wu X, Su L, Raley C et al (2016) Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 34(4):424–429PubMedPubMedCentralCrossRef

100.

De Ravin SS, Li L, Wu X, Choi U, Allen C, Koontz S, Lee J et al (2017) CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med 9(372):eaah3480PubMedCrossRef

101.

Sweeney CL, Zou J, Choi U, Merling RK, Liu A, Bodansky A, Burkett S, Kim JW, de Ravin SS, Malech HL (2017) Targeted repair of CYBB in X-CGD iPSCs requires retention of Intronic sequences for expression and functional correction. Mol Ther 25(2):321–330PubMedPubMedCentralCrossRef

Titel: Chronic Granulomatous Disease: a Comprehensive Review
verfasst von: Hsin-Hui Yu
Yao-Hsu Yang
Bor-Luen Chiang
Publikationsdatum: 10.06.2020
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2021
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-020-08800-x

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chronic Granulomatous Disease: a Comprehensive Review

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge

Maternal Nutritional Status and Development of Atopic Dermatitis in Their Offspring

Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies

Next-Generation Sequencing in the Field of Primary Immunodeficiencies: Current Yield, Challenges, and Future Perspectives

Clinical Manifestations and Management of Pediatric Behçet’s Disease

Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO